Table 5

Indirect comparison results: duloxetine vs. pregabalin.

Outcome

Indirect treatment comparison (δ)

Mean (median)

95% CI for δ

Between-study variance (τ 2)

Mean (median)

95% CI for τ2


Efficacy

Reduction in 24-hour pain intensity

-0.248 (0.248)

(-0.667;0.162)

0.052 (0.024)

(0.001;0.252)

Response

0.033 (0.034)

(-0.393;0.451)

0.075 (0.052)

(0.001;0.287)

PGI-I/PGI-C

0.542 (0.545)

(0.016;1.060)

0.025 (0.009)

(0.001;0.151)


Tolerability

Premature study discontinuation due to:

- Lack of efficacy

-0.251 (-0.235)

(-1.288;0.717)

0.058 0.015)

(0.001;0.381)

- Adverse events

0.152 (0.154)

(-0.505;0.790)

0.039 (0.012)

(0.001;0.243)

- Other

-0.068 (-0.069)

(-0.735;0.589)

0.045 (0.013)

(0.001;0.281)

Diarrhoea

0.886 (0.885)

(-0.414; 2.183)

0.248 (0.050)

(0.001; 1.628)

Dizziness

-1.084 (-1.074)

(-1.903; -0.317)

0.075 (0.020)

(0.001; 0.477)

Headache

0.700 (0.704)

(-0.078; 1.458)

0.037 (0.011)

(0.001; 0.235)

Somnolence

-0.554 (-0.552)

(-1.458; 0.328)

0.052 (0.013)

(0.001; 0.347)


Note:

δ is the mean difference in treatment effect between DLX and each comparator.

τ2 is between-study heterogeneity.

Quilici et al. BMC Neurology 2009 9:6   doi:10.1186/1471-2377-9-6

Open Data